Topic prioritisation

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Decision date

Decision date

Prioritisation programme

Prioritisation programme

Decision

Decision

Showing 1 to 25 of 112

TitlePrioritisation programmeDecisionDecision date
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]Medicines evaluationNot selected
Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]Medicines evaluationNot selected
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]Medicines evaluationNot selected
Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]Medicines evaluationNot selected
Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]Medicines evaluationNot selected
Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]Medicines evaluationNot selected
Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]Medicines evaluationNot selected
SEEG-guided radiofrequency thermocoagulation in refractory epilepsyInterventional proceduresAwaiting decision
Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]None selectedNot selected
Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]None selectedNot selected
Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]None selectedNot selected
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]None selectedNot selected
Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]None selectedNot selected
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]None selectedNot selected
Modified release hydrocortisone capsules for treating adrenal insufficiency in people 12 years and over [TSID12254]None selectedNot selected
Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]None selectedNot selected
Dermal allograft augmentation in proximal humerus fracture fixationNone selectedAwaiting decision
Ferric citrate for managing iron and serum phosphorus levels in anaemia associated with chronic kidney disease [TSID12221]None selectedNot selected
Oral cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12214]None selectedNot selected
Long-acting injections of cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12219]None selectedNot selected
Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]None selectedNot selected
Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]None selectedNot selected
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]None selectedNot selected
Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]None selectedNot selected
Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106None selectedNot selected

Results per page

  1. 10
  2. 25
  3. 50
  4. All